Resultados globales: 2 registros encontrados en 0.02 segundos.
Artículos, Encontrados 2 registros
Artículos Encontrados 2 registros  
1.
10 p, 1.9 MB Nuclear IGF-1R predicts chemotherapy and targeted therapy resistance in metastatic colorectal cancer / Codony-Servat, Jordi (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Cuatrecasas, Miriam ; Asensio, Elena (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Montironi, Carla (Hospital Clínic i Provincial de Barcelona) ; Martínez Cardús, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Marín Aguilera, Mercedes (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Horndler, Carlos (Hospital Universitario Miguel Servet (Saragossa)) ; Martínez Balibrea, Eva (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Rubini, Michele (Department of Experimental and Diagnostic Medicine, University of Ferrara) ; Jares, Pedro (Hospital Clínic i Provincial de Barcelona) ; Reig, Oscar (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Victoria, Iván (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Gaba, Lydia (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Martín Richard, Marta (Institut d'Investigació Biomèdica Sant Pau) ; Alonso, Vicente (Hospital Universitario Miguel Servet (Saragossa)) ; Escudero, Pilar (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ; Fernández-Martos, Carlos (Fundació Institut Valencià d'Oncologia) ; Feliu, Jaime (Centro de Investigación Biomédica en Red de Cáncer) ; Méndez, Jose Carlos (Centro Oncológico de Galicia) ; Méndez, Miguel (Hospital Universitario de Móstoles (Madrid)) ; Gallego, Javier (Hospital General Universitario de Elche) ; Salud, Antonieta (Hospital Arnau de Vilanova (Lleida, Catalunya)) ; Rojo, Federico (Fundacion Jimenez Diaz) ; Castells, Antoni (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Prat, Aleix (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; García-Albéniz, Xabier (Harvard T.H. Chan School of Public Health (Boston, Estats Units d'Amèrica)) ; Camps, Jordi (Universitat Autònoma de Barcelona. Departament de Biologia Cel·lular, de Fisiologia i d'Immunologia) ; Maurel, Joan (Institut d'Investigacions Biomèdiques August Pi i Sunyer) ; Universitat Autònoma de Barcelona
Although chemotherapy is the cornerstone treatment for patients with metastatic colorectal cancer (mCRC), acquired chemoresistance is common and constitutes the main reason for treatment failure. Monoclonal antibodies against insulin-like growth factor-1 receptor (IGF-1R) have been tested in pre-treated mCRC patients, but results have been largely deceiving. [...]
2017 - 10.1038/bjc.2017.279
British Journal of Cancer, Vol. 117 (november 2017) , p. 1777-1786  
2.
9 p, 435.9 KB Prediction of overall survival in stage II and III colon cancer beyond TNM system : a retrospective, pooled biomarker study / Dienstmann, Rodrigo. (Hospital Universitari Vall d'Hebron) ; Mason, M. J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Sinicrope, F. A. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Phipps, A. I. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Tejpar, Sabine (University Hospitals Gasthuisberg (Leuven, Bélgica)) ; Nesbakken, A. (Oslo University Hospital (Oslo, Noruega)) ; Danielsen, S. A. (Oslo University Hospital (Oslo, Noruega)) ; Sveen, A. (Oslo University Hospital (Oslo, Noruega)) ; Buchanan, Daniel D (The University of Melbourne) ; Clendenning, M. (The University of Melbourne) ; Rosty, C. (The University of Melbourne) ; Bot, Brian M (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Alberts, S. R. (Mayo Clinic and Mayo Comprehensive Cancer Center, Rochester, USA) ; Milburn Jessup, J. (National Cancer Institute (Rockville, Estats Units d'Amèrica)) ; Lothe, R. A. (Oslo University Hospital (Oslo, Noruega)) ; Delorenzi, Mauro (SIB Swiss Institute Bioinformatics, Lausanne, Switzerland) ; Newcomb, P. A. (Fred Hutchinson Cancer Research Center, Seattle, USA) ; Sargent, D. (Mayo Clinic, Rochester, USA) ; Guinney, J. (Computational Oncology, Sage Bionetworks, Seattle, USA) ; Universitat Autònoma de Barcelona
TNM staging alone does not accurately predict outcome in colon cancer (CC) patients who may be eligible for adjuvant chemotherapy. It is unknown to what extent the molecular markers microsatellite instability (MSI) and mutations in BRAF or KRAS improve prognostic estimation in multivariable models that include detailed clinicopathological annotation. [...]
2017 - 10.1093/annonc/mdx052
Annals of oncology, Vol. 28 (february 2017) , p. 1023-1031  

¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.